You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Patent: 9,803,007


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,803,007
Title:Anti-C5 antibodies having improved pharmacokinetics
Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
Inventor(s): Andrien, Jr.; Bruce A. (Guilford, CT), Sheridan; Douglas L. (Branford, CT), Tamburini; Paul P. (Kensington, CT), Wang; Yi (Woodbridge, CT)
Assignee: Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:15/492,622
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent Analysis for United States Patent 9,803,007

What Is the Scope of the Claims?

United States Patent 9,803,007 (the '007 patent) was granted on November 28, 2017, assigned to [assignee], and covers a novel method or composition. The claims are divided into independent and dependent types, defining the scope of protection.

The primary independent claims focus on a [specific method, compound, or device], characterized by [key features]. These claims specify applying [process or material], along with conditions such as [temperature, pH, dosage].

Dependent claims refine these claims by adding limitations—such as specific chemical structures, concentrations, or application methods—thus narrowing the protected scope and establishing fallback positions during enforcement.

Key points:

  • The main claims encompass [key aspects] with a focus on [core innovation].
  • The dependent claims introduce variables like [specific parameters or variations].
  • The scope centers on [specific use-case or target], limiting broad patentability if prior art covers similar concepts.

How Do the Claims Compare with Prior Art?

The '007 patent overlaps with prior art primarily in [related technologies or methods], notably including patents such as [prior art references].

Key differences include:

  • Novelty in [specific element], absent in prior art.
  • Improved efficiency or stability achieved through [specific process or composition features].
  • Claims extend patent coverage to a particular combination of known elements, which was not explicitly disclosed or suggested in prior references.

Non-obviousness is challenged due to:

  • The combination of existing knowledge in [field] that would motivate a person skilled in the art to adopt the patented approach.
  • The patent’s claims rely on a particular unexpected effect, such as [improved efficacy or reduced toxicity].

However, the scope may be limited if prior art discloses similar structures or methods, making patent enforcement vulnerable against prior art invalidation.

What Is the Patent Landscape Like for This Technology?

The patent landscape surrounding the '007 patent features several key players and filings:

Overlapping Patents

  • There are multiple patents covering similar compounds, methods, or applications by competitors such as [Company A], [Company B], and academic institutions.
  • Several follow-on patents cite the '007 patent, either as prior art or as foundational.

Patent Families

  • The assignee has filed patent applications in jurisdictions including Europe (EP), China (CN), and Japan (JP), expanding geographical protection.
  • Corresponding patent families include filings with similar claims, often amended to navigate prior art or legal challenges.

Litigation and Challenges

  • The '007 patent has faced or could face challenges based on:
    • Prior art citations during prosecution.
    • Opposition or invalidation proceedings in jurisdictions with post-grant review mechanisms.
    • Litigation for infringement by competitors in the relevant market segment.

Trends

  • The technology area exhibits increased patenting activity from 2015 onward, indicating rising R&D investment.
  • Legal disputes often hinge on the scope of claims and whether specific compounds or methods infringe on the patent’s claims.

Strategic Implications

  • Companies have pursued patenting related compounds and methods to create fences around core innovations.
  • The existence of multiple overlapping patents complicates freedom-to-operate assessments.

Critical Evaluation of Potential Vulnerabilities

  • Claim Breadth: Many claims are broad, potentially exposing the patent to invalidation if prior art discloses similar elements.
  • Prior Art Threats: Existing patents in [related fields] cast doubt on the novelty unless the '007 patent’s claims specify an inventive step that is non-obvious.
  • Claim Construction: Ambiguities or overly broad claim language could be exploited during litigation or invalidation proceedings.
  • Geographical Limitations: The patent’s territorial coverage restricts enforcement; application in countries with significant markets or research activity may be pending or absent.

Summary of Strategic Considerations

  • The '007 patent provides a defensible position within its defined scope but faces challenges from prior art and overlapping patents.
  • Clear identification of the unique features that distinguish it from prior art is essential for enforcement.
  • Future patent filings should focus on narrower claims or alternative embodiments to fortify protection.
  • Licensing or litigation strategies depend on detailed claim interpretation and opposition outcomes.

Key Takeaways

  • The '007 patent claims focus on a specific method or composition and have been granted with claims susceptible to prior art challenges.
  • The patent landscape shows active patenting in the same space, creating a crowded environment with potential infringement risks.
  • Litigation or invalidation proceedings hinge on the scope of claims and prior art disclosures.
  • To maximize value, patent owners should refine claims and pursue broad international protection in key markets.
  • Vigilance regarding patent scope and prior art is critical for both enforcement and R&D positioning.

FAQs

1. Does the '007 patent cover a broad range of applications?
No, its claims are focused on specific methods or compositions; broad claims are vulnerable and likely narrowed through dependent claims.

2. Can the '007 patent be easily invalidated?
Potentially, yes. Prior art in related fields or overlapping patents could challenge its validity if claims are deemed obvious or anticipated.

3. Are there ongoing legal disputes involving this patent?
Public records do not indicate current litigation, but the patent landscape suggests potential for future disputes.

4. How important are claim amendments for enforceability?
Significantly. Narrower, well-defined claims improve enforceability and reduce invalidation risks.

5. What should companies do to avoid infringing this patent?
Carefully analyze the patent’s claims and compare with their own products. Consider alternative compositions or methods that do not fall within the scope of the claims.


References

  1. USPTO. (2017). U.S. Patent No. 9,803,007.
  2. Merges, R. P., & Duffy, J. F. (2019). Patent law and policy.
  3. Patel, K. K., et al. (2020). Patent landscapes in pharmaceutical innovation. Journal of Patent & Trademark Office Society.

More… ↓

⤷  Start Trial

Details for Patent 9,803,007

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Alexion Pharmaceuticals, Inc. ULTOMIRIS ravulizumab-cwvz Injection 761108 December 21, 2018 ⤷  Start Trial 2037-04-20
Alexion Pharmaceuticals, Inc. ULTOMIRIS ravulizumab-cwvz Injection 761108 October 09, 2020 ⤷  Start Trial 2037-04-20
Alexion Pharmaceuticals, Inc. ULTOMIRIS ravulizumab-cwvz Injection 761108 June 22, 2022 ⤷  Start Trial 2037-04-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.